Home/Pipeline/Obesity Target Discovery Collaboration

Obesity Target Discovery Collaboration

Obesity

Target Discovery/PreclinicalActive

Key Facts

Indication

Obesity

Phase

Target Discovery/Preclinical

Status

Active

Company

Fauna Bio

About Fauna Bio

Fauna Bio is a private, preclinical-stage biotech founded in 2018 and headquartered in Emeryville, California. The company has pioneered a unique drug discovery platform that mines genetic data from a proprietary biobank of extreme mammals to find novel targets for diseases like obesity, fibrosis, and muscle wasting. Its business model is a hybrid of platform licensing and therapeutic development, evidenced by a significant $494M+ partnership with Eli Lilly in obesity. Fauna Bio also engages in innovative space health research funded by NASA and other space agencies, exploring the protective effects of hibernation for astronauts.

View full company profile

Therapeutic Areas

Obesity Metabolic Disorders Fibrosis Muscle Wasting Regenerative Medicine

Other Obesity Drugs

Drug	Company	Phase	Status
LET003	Harbour BioMed	Discovery	Active (Global)
LET001	Harbour BioMed	Discovery	Active (Global)
RGT-075	Regor Therapeutics	Phase 2b	Active
Anti‑Obesity Oral Drug	Premas Biotech	Phase 1	Active
GLP-1 variants	Heligenics	Discovery	Active
MYO Platform (Metabolic Disease)	Renbio	Pre-clinical	Active
Obesity Clinical Trials	IMA Clinical Research	Not Applicable (Service)	Active
KAYO-2000	KayoThera	Preclinical	Active
MVD-1 (SANA)	Eolo Pharma	Phase 1	Active
GIP-neutralizing antibody	Helicore Biopharma	Pre-clinical	Active
Antral Gastroplasty / Endoscopic Sleeve	Endo-TAGSS	Pre-clinical	Active
Undisclosed siRNA Programs	Moonwalk Biosciences	Pre-clinical	Active